Rheumatic Disease eJournal Club
Initiation of Tumor Necrosis
Factor-α Antagonists and the Risk
of Hospitalization for Infection in Patients
With Autoimmune Diseases
Publication:
Grijalva CG, Chen L, Delzell E, et al. JAMA. 2011 Nov 6. doi: 10.1001/jama.2011.1692.
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: December 20, 2011
Expiration Date: December 20, 2012
Estimated Time of Completion: 30 minutes
Description
The purpose of this activity is to discuss a study that evaluates the risk of hospitalization for serious infection in patients starting a TNF inhibitor (TNFi).
Learning Objectives
- Outline the design of a study assessing the risk of hospitalization for serious infection in patients starting a TNFi.
- Describe the probability of hospitalization for serious infection in patients starting a TNFi or a nonbiologic agent.
- Discuss the most common types of serious infections reported in patients starting a TNFi or biologic.
Target Audience
This activity is directed to rheumatologists, primary care physicians, and other clinicians who treat patients with rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), gout, systemic lupus erythematosus (SLE), and ANCA-associated vasculitis.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
R.J. Fasenmyer Chair of Clinical Immunology
Vice Chairman
Department of Rheumatic and Immunologic Diseases
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Cleveland Clinic
Cleveland, Ohio
Faculty
Kevin L. Winthrop, MD, MPH
Assistant Professor
Department of Medicine, Division of Infectious Diseases; and
Department of Public Health and Preventive Medicine
Oregon Health and Science University
Portland, Oregon
Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have relationships which, in the context of his presentation, could be perceived as a potential conflict of interest:
| Leonard H. Calabrese, DO | |||
| Amgen Inc.; Bristol-Myers Squibb Company; Centocor, Inc.; Pfizer Inc; Roche-Genentech |
Consulting | ||
| Amgen Inc.; Bristol-Myers Squibb Company; Centocor, Inc.; Pfizer Inc; Roche-Genentech |
Teaching and Speaking | ||
The following faculty has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
Kevin L. Winthrop, MD, MPH
All other planners, CME staff, and content reviewers have no relevant financial relationships to disclose.
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from Genentech, Inc.
This CME activity was produced by the
Cleveland Clinic Center for Continuing Education
and
